Yesterday it was reported that the Executive Vice-President & Chief Financial Office of Bausch Health Companies (BHC), Paul Herendeen, exercised options to sell 1,642 BHC shares for a total transaction value of $26.12K.
In addition to Paul Herendeen, 4 other BHC executives reported Sell trades in the last month. Following Paul Herendeen’s last BHC Sell transaction on March 12, 2020, the stock climbed by 0.7%.
See today’s analyst top recommended stocks >>
The company has a one-year high of $31.97 and a one-year low of $11.15.
Based on 7 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $28.86, reflecting a -42.8% downside.
The insider sentiment on Bausch Health Companies has been negative according to 151 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Paul Herendeen’s trades have generated a 19.0% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets.
Read More on BHC: